OMEICOS Therapeutics GmbH Company Profile, Contacts & Intelligence

OMEICOS Therapeutics GmbH Overview

OMEICOS Therapeutics has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat mitochondrial dysfunction, inflammatory, cardiovascular and other diseases. Epoxyeicosanoids activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts. The currently active PMD-OPTION Phase 2a clinical study is evaluating OMEICOS’ lead development program OMT-28 in patients with Primary Mitochondrial Disease.

Headquarters

Berlin, De

Website

omeicos.com

Industry

Biotechnology Research

Founded

2013

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Phone Number

Available in AeroLeads

Company Email

Available in AeroLeads

OMEICOS Therapeutics GmbH Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

OMEICOS Therapeutics GmbH People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

OMEICOS Therapeutics GmbH Workforce Composition

Seniority breakdown across 6 visible profiles.

Compare Similar Companies to OMEICOS Therapeutics GmbH

Explore companies in related markets and compare their industry and employee estimates.